Proper diagnosis effective for dry eye therapy

Article

A new golden age is here: the Golden Age of Dry Eye Management, according to one optometrist.

"We have large numbers of individuals from the baby boomer generation who are entering the dry eye time in their lives, and there's a greater awareness of dry eye in the first place, even with younger people," said Dr. Schachet, Eyecare Consultants-Vision Source, Englewood, CO. "We not only have the opportunity to dramatically help our patients, but also to own this segment of the marketplace."

Dr. Schachet said that with growing awareness of dry eye disease has come growing knowledge and changing paradigms, along with a new name: ocular surface disease.

The new paradigm begins with determining the etiology. The two major types of dry eye are aqueous deficient and evaporative. A correct diagnosis is essential to establish the proper therapy.

"If you don't have the proper diagnosis in the first place it doesn't matter what you do," Dr. Schachet said. "There's no way to 'shotgun' this and be effective."

Make the proper diagnosis

According to Dr. Schachet, history is the key to making the proper diagnosis. He recommended including these questions:

"Listen to the patient," Dr. Schachet said. "Covering key points in a thorough history will help you determine where to go with your testing."

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.